Psychiatr. praxi. 2012;13(4):160-163

Atypical antipsychotics and diabetes mellitus

doc.MUDr.Miroslav Zeman, CSc.1, doc.MUDr.Roman Jirák, CSc.2
1 IV. interní klinika 1. LF UK a VFN Praha
2 Psychiatrická klinika 1. LF UK a VFN Praha

The risk of development of type 2 diabetes (DM2) is significantly increased in the patients suffering from psychotic diseases such as schizophrenia,

depressive disorder or bipolar affective disorder. There are more of the causes of this phenomenon. The patients with abovementioned

diseases are characterized by unhealthy lifestyle and also suffer from an increased occurence of the components of the metabolic

syndrome (MetS). Treatment with some atypical antipsychotics (AAP) increases the risk of development of DM2. Atypical antipsychotics

can be divided into several groups according to their influencing on the receptors of the neurotransmitters. Spectrum of the receptors,

influenced by the individual AAP, determines their effects on the weight gain, plasma lipid levels and the risk of DM2 development.

Keywords: psychotic disorders, atypical antipsychotics, weight gain, dyslipidemia, type 2 diabetes mellitus

Published: November 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Zeman M, Jirák R. Atypical antipsychotics and diabetes mellitus. Psychiatr. praxi. 2012;13(4):160-163.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Osby U, Correia N, Brandt L, Ekbom A, Sparen P. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 2000; 45: 21-28. Go to original source... Go to PubMed...
    2. Rugulies R. Depression as a predictor for coronary heart disease. A review and meta-analysis. Am. J. Prev. Med. 2002; 23: 51-61. Go to original source... Go to PubMed...
    3. Connolly M, Kelly C. Lifestyle and physical health in schizophrenia. Advances in Psychiatric Treatment 2005; 11: 125-132. Go to original source...
    4. Ryan MCM, Collins P, Thakore JH. Impaired fasting glucose-tolerance in first-episode, drug naive patients with schizophrenia. Am. J. Psychiatry 2003; 160: 284-289. Go to original source... Go to PubMed...
    5. Mezuk B, Eaton WW, Albrecht S, Golden SH. Depression and type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care 2008; 31: 2383-2390. Go to original source... Go to PubMed...
    6. Kinder LS, Carnethon MR, Palaniappan LP, et al. Depression and the metabolic syndrome in young adults: findings from the Third National Health and Nutrition Examination Survey. Psychosom Med 2004; 66: 316-322. Go to original source... Go to PubMed...
    7. Reaven GM. Metabolic syndrome. Pathophysiology and implications for management of cardiovascular disease. Circulation 2002; 106: 286-288. Go to original source... Go to PubMed...
    8. Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk: a systematic review and meta-analysis. J Am Coll Cardiol 2010; 56: 1113-1132. Go to original source... Go to PubMed...
    9. Ford ES, Li C, Sattar N. Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care 2008; 31: 1898-1904. Go to original source... Go to PubMed...
    10. Mukherjee S, Schnur DB, Reddy R. Family history of type 2 diabetes in schizophrenic patients. Lancet 1989; 1: 495. Go to original source... Go to PubMed...
    11. Spelman LM, Walsh PI, Sharifi N, Collins P, Thakore JH. Impaired glucose tolerance in first-episode drug-naďve patients with schizophrenia. Diabet Med. 2007; 24: 481-485. Go to original source... Go to PubMed...
    12. Holt RI, Bushe C, Citrome L. Diabetes and schizophrenia 2005: are we any closer to understanding the link? J Psychopharmacol 2005; 19(6 Suppl): 56-65. Go to original source... Go to PubMed...
    13. Suvisaari JM, Sarni SI, Perala J, et al. Metabolic syndrome among persons with schizophrenia and other psychotic disorders in a general population survey. J Clin Psychiatry 2007; 68(7): 1045. Go to original source... Go to PubMed...
    14. Svačina Ś. Metabolické účinky psychofarmak. Triton, Praha, 2004: 187.
    15. Perez-Iglesias R, Vazquez-Barquero JL, Amado JA, et al. Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment. J Clin Psychopharmacol 2008; 28: 289-295. Go to original source... Go to PubMed...
    16. Correll CU, Lencz T, Malhotra AK. Antipsychotic drugs and obesity. Trends Mol Med. 2011; 17: 97-107. Go to original source... Go to PubMed...
    17. Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003; 28(3): 519-526. Go to original source... Go to PubMed...
    18. Deng C, Weston-Green K, Huang XF. The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain? Prog Neuropsychopharmacol Biol Psychiatry 2010; 34(1): 1-4. Go to original source... Go to PubMed...
    19. Wang B, Chehab FF. Deletion of the serotonin 2c receptor from transgenic mice overexpressing leptin does not affect their lipodystrophy but exacerbates their diet-induced obesity. Biochem Biophys Res Commun. 2006; 351(2): 418-423. Go to original source... Go to PubMed...
    20. Kirk SL, Glazebrook J, Grayson B, Neill JC, Reynolds GP. Olanzapine-induced weight gain in the rat: role of 5-HT2C and histamine H1 receptors. Psychopharmacology (Berl). 2009; 207(1): 119-125. Go to original source... Go to PubMed...
    21. Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients metabolic outcomes after 1 year. J Clin Psychiatry 2002; 63: 425-433. Go to original source... Go to PubMed...
    22. Shirzadi AA, Ghaemi SN. Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome. Harv Rev Psychiatry 2006; 14(3): 152-164. Go to original source... Go to PubMed...
    23. Wu RR, Zhao JP, Liu ZN, et al. Effects of typical and atypical antipsychotik on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology 2006; 186: 572-578. Go to original source... Go to PubMed...
    24. Starrenburg FCJ, Bogers JPAM. How can antipsychotics cause diabetes mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins. Eur Psychiatry 2009; 24: 164-170. Go to original source... Go to PubMed...
    25. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-1223. Go to original source... Go to PubMed...
    26. Citrome L, Jaffe A, Levine J, Allingham B, Robinson J. Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. Psychiatr Serv 2004; 55: 1006-1013. Go to original source... Go to PubMed...
    27. Přikryl R. Léčba atypickými antipsychotiky a jejich volba podle spektra nežádoucích účinků. PsychiatrPraxi 2009; 10: 20-23.
    28. Nasrallah HA. Metabolic findings from the CATIE trial and their relation to tolerability. CNS Spectr 2006; 11(Suppl 7): 32-39. Go to original source... Go to PubMed...
    29. Ford ES, Li C, Sattar N. Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care 2008; 31: 1898-1904. Go to original source... Go to PubMed...
    30. Houseknecht KL, Robertson AS, Zavadoski W, et al. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology 2007; 32: 289-297. Go to original source... Go to PubMed...
    31. Matsui-Sakata A, Ohtani H, Sawada Y. Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus. Drug Metab Pharmacokinet 2005; 20: 368-378. Go to original source... Go to PubMed...
    32. Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 2004; 3: 353-359. Go to original source... Go to PubMed...
    33. Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Molecular Psychiatry 2008; 13: 27-35. Go to original source... Go to PubMed...
    34. Panariello F, Perruolo G, Cassese A, et al. Clozapine impairs insulin action by up-regulating Akt phosphorylation and Ped/ Pea-15 protein abundance. J Cell Physiol. 2012; 227(4): 148592. doi: 10.1002/jcp.22864. Go to original source... Go to PubMed...
    35. Silvestre JS, Prous J. Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes. Methods Find Exp Clin Pharmacol 2005; 27: 289-304. Go to original source... Go to PubMed...
    36. Oriot P, Feys JL, Mertens de Wilmars S, et al. Insulin sensitivity, adjusted â-cell function and adiponectinaemia among lean drug-naive schizophrenic patients treated with atypical antipsychotic drugs: A nine-month prospective study. Diabetes Metab 2008; 34: 490-496. Go to original source... Go to PubMed...
    37. Albaugh VL, Singareddy R, Mauger D, Lynch CJ. A Double Blind, Placebo-Controlled, Randomized Crossover Study of the Acute Metabolic Effects of Olanzapine in Healthy Volunteers. PLoS ONE 2011; 6(8): e22662. Go to original source... Go to PubMed...
    38. Teff KL, Kim SF. Atypical antipsychotics and the neural regulation of food intake and peripheral metabolism. Physiol Behav 2011; 104: 590-598. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.